ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: A prospective study

Analytical and Quantitative Cytology and Histology

Volumn 32, Issue 1, 2010, Pages 45-52

  Li, Hong Xia ^a   Li, Min ^a   Li, Chang Ling ^a   Ma, Jian Hui ^a   Wang, Ming Rong ^a   Rao, Jianyu ^b   Pan, Qin Jing ^a  

^a CANCER HOSPITAL   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bladder cancer; CK20; uCyt+; Urine; Urothelial carcinoma

Indexed keywords

CYTOKERATIN 20;

ADULT; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYT; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE CYTOLOGY; UROTHELIAL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; CYTODIAGNOSIS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KERATIN-20; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 77951128077     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156
2. Planz B, Jochims E, Deix T, Caspers HP, Jakse G, Boecking A: The role of urinary cytology for detection of bladder cancer. Eur J Surg Oncol 2005;31:304-308 (Pubitemid 40361523)
3. Murphy WM: Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 1990;21:886-896
4. Wright RG, Halford JA: Evaluation of thin-layer methods in urine cytology. Cytopathology 2001;12:306-313 (Pubitemid 33757965)
5. Lekili M, Sener E, Demir MA, Temeltas G, Muezzinoglu T, Buykusu C: Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. Urol Res 2004;32:124-128 (Pubitemid 38915403)
6. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson SL, Lieber M, Soloway M, Flom K: Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950-1954
7. Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C: Comparative evaluation of the diagnostic performance of the BTA stat test, NMP 22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 2001;2:470-475 (Pubitemid 32652225)
8. Tetu B, Tiguert R, Harel F, Fradet Y: ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 2005;18:83-89 (Pubitemid 40128099)
9. Eissa S, Kassim S, EI-Ahmady O: Detection of bladder tumours: Role of cytology, morphology-based assays, biochemical and molecular markers. Curr Opin Obstet Gynecol 2003;15:395-403 (Pubitemid 37330384)
10. Lodde M, Mian C, Negri G, Berner L, Maffei N, Lusuardi L, Palermo S, Marberger M, Brssner C, Pycha A: Role of uCyt in the detection and surveillance of urothelial carcinoma. Urol 2003;61:243-247 (Pubitemid 36151760)
11. Piaton E, Daniel L, Verriele V, Dalifard I, Zimmermann U, Renaudin K, Gobet F, Caratero A, Desvaux D, Pouille Y, Seigneurin D: Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: Results of a French Prospective Multicenter Study. Lab Invest 2003;83:845-852 (Pubitemid 36723693)
12. Fradet Y, Lockhard C: Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol 1997;4:400-405
13. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberg M: ImmunoCyt: A new tool for detection of transitional cell cancer of the urinary tract. J Urol 1999;161:1486-1489 (Pubitemid 29420801)
14. Lin S, Hirschowitz SL, Williams C, Shintako P, Said J, Rao JY: Cytokeratin 20 as an immunocytochemical marker for detection of urothelial carcinoma in atypical cytology: Preliminary retrospective study on archived urine slides. Cancer Detect Prev 2001;25:202-209
15. Melissourgos ND, Kastrinakis NG, Skolarikos A, Pappa M, Vassilakis G, Gorgoulis VG, Salla C: Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder. Urology 2005;66:536-541 (Pubitemid 41242319)
16. Eissa S, Kassim SK, Labib RA, El-Khouly IM, Ghaffer TM, Sadek M, Razek OA, El-Ahmady O: Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer 2005;103:1356-1362
17. Harnden P, Mahmood N, Southgate J: Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 1999;353:974-977
18. Geisinger KR, Stanley MW, Raab SS, Silverman JF, Abati A: Modern Cytopathology. Philadelphia, Churchill Livingstone, 2003, pp 235-242
19. Bhatia A, Dey P, Kumar Y: Morphometry of urinary atypical cells. Anal Quant Cytol Histol 2007;29:183-184
20. Requena MJ, Alvarez-Kindelan J, Blanca A: Immunohistochemical markers in the evaluation of tumors of the urinary bladder: A review. Anal Quant Cytol Histol 2007;29:380-382
21. Chadwick B, Willmore-Payne C, Holden J, Layfield L: Fluorescence in situ hybridization determination of aneusomy: Criteria and technical considerations. Anal Quant Cytol Histol 2007;29:351-357
22. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, Procop GW, Jones JS, Ulchaker J, Zippe CD, Tubbs RR: Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101-2105
23. Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A: Clinical utility of multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences compared with urinary cytology. Eur Urol 2002;42:547-552